



ASX Release

Market Update on Commercialisation Progress of Felix Device

Sydney, Thursday 22 February 2018

Memphasys announces that its re-usable cartridge prototype device has successfully completed optimisation studies. Memphasys has now engaged its engineering development partner, Hydrix, to commence development of the Felix clinical device, which will use sterile, disposable cartridges. These consumable cartridges are positioned to build a strong recurring revenue business model for MEM.

When completed, the device will be placed into selected leading key opinion leading IVF clinics globally and through *in-vitro* studies to be conducted in these clinics its performance in preparing sperm for IVF will be assessed and compared with the current lab-based methods which are labor intensive, costly and contribute to sperm DNA damage.

The attached presentation provides an update on the development of the Felix clinical device.

For further information please contact:

Alison Coutts
Executive Chairman
+61 2 8415 7300
alison.coutts@memphasys.com

About Memphasys:

Memphasys Limited (**ASX: MEM**) specialises in biological separations for high value commercial applications. The Company's patented membrane processes in combination with electrophoresis, the application of an electrical potential difference across a fluid, enable the separation of high value substances or contaminants from the fluid in which they are contained.

The main application of the technology is the separation of the most viable sperm cells for artificial reproduction, most particularly for human IVF.

Memphasys Limited
30-32 Richmond Road
Homebush West NSW 2140

Postal Address
P.O. Box 2202
Homebush West NSW 2140

Contact Details
P +612 8415 7300
F +612 8415 7399

E info@memphasys.com
W memphasys.com
ABN 33 120 047 556



Memphasys

ASX: MEM

Developing a unique device to treat male infertility

Alison Coutts

Executive Chairman, *Memphasys Limited*

Feb 2018



Disclaimer

This presentation is not and does not form part of any offer, invitation or recommendation in respect of securities. Any decision to buy or sell Memphasys securities or other products should be made only after seeking appropriate financial advice. Reliance should not be placed on information or opinions contained in this presentation and subject only to any legal obligation to do so, the Company does not accept any obligation to correct or update them.

This presentation does not take into consideration the investment objectives, financial situation or particular needs of any particular investor.

To the fullest extent permitted by law, Memphasys and its affiliates and their

respective officers, directors, employees and agents, accept no responsibility for any information provided in this presentation, including any forward looking information, and disclaim and liability whatsoever (including for negligence) for any loss howsoever arising from any use of this presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this presentation.

Pressing need for improvements in IVF

IVF:

- **Is expensive**
 - up to \$10,000 per try, average of 2.2 tries before successful pregnancy, success not always possible
- **Is physically and emotionally draining**
- **Increases risk of miscarriage and chance of having genetically impaired offspring**

What if there were a technology that:

- **Increased the likelihood of pregnancy, and**
- **Enabled the birth of a genetically healthy baby?**


What would that be worth?

Need to improve male fertility

Male infertility

- Is a factor in nearly 50% of infertile couples
- Affects ~1/3rd of men over 40
- Has been rapidly increasing for the past few decades¹
 - environmental and lifestyle factors are likely causes
- Is strongly linked with lifestyle factors e.g. obesity, smoking; and with chronic disease e.g. cardiovascular disease and diabetes
- No meaningful advances in male infertility treatments since the advent of IVF

¹. eg Chinese male sperm counts have halved over the past 20 years; developed countries also have rapidly increasing infertility rates



Sperm quality,
rather than quantity,
is the issue

Human ART¹ market is large and rapidly growing; the accessible market for MEM is also large

Human ART market statistics

Couples with fertility issues	>50 million
Australian couples seeking IVF treatments; Children born by IVF	1 in 6 1 in 25 in Australia 1 in 15 in Denmark
IVF treatments market size 2012/2020	US\$9.3bn / US\$21.6bn (F)
Estimated no. cycles per year, worldwide	~6 million
IVF consumables market	US\$450m
Approx. consumables cost per IVF cycle	\$400
Av. cost to patient per cycle: developing/developed countries	~\$1,500 / ~\$10,000 (india) / (Aust/USA)

MEM's accessible Market:

- MEM's initial market(IVF, ICSI²): > \$600 million
- Plus IUI³ market: ~ \$1.2 billion

¹Assisted Reproductive Technology (ie all assisted reproductive technologies)


²Intra-Cytoplasmic Injection

³Intra-Uterine Insemination

MEM's technology provides better chance of success

Memphasys

- Memphasys has unique, patented IP for separating the 'best' quality sperm from IVF semen samples
 - The technology was developed in conjunction with world renowned fertility expert, Prof John Aitken
- The best quality sperm have the most negative cell surface charge – a sign they have been properly developed and have minimum DNA damage
- Sperm DNA damage
 - greatly increases with paternal age
 - is a major factor in the inability to conceive, to miscarry or to give birth to a child with genetic damage e.g. dwarfism, bipolar disease, epilepsy, autism etc



Memphasys' 'Felix' device has major advantages over current IVF sperm processing methods¹

Memphasys

For personal use only

Current IVF sperm processing methods ¹	MEM's 'Felix' device
30-40 minutes of slow multi-stage manual processes	5 minute automated process
Involve washing and centrifuging which damage DNA	Gentle, no centrifuging, no cell damage
Do not remove DNA-damaging semen constituents (mostly white blood cells and dying or dead sperm cells)	Removes the DNA-damaged sperm, and unwanted semen constituents
Both techniques cannot treat some poor sperm samples; 'Swim up' has very limited use.	Can be used on nearly all poor sperm types, and with the different IVF techniques
DNA-damaged sperm can unknowingly be selected DNA damage decreases pregnancies; increases probability of genetically damaged progeny	Selects best quality, least DNA-damaged sperm Likely to increase probability of pregnancy and birth of healthy baby

¹. *Differential Gradient Centrifugation ('DGC') / 'Swim Up'*

'Felix' device key development progress to date


In 2008 in a small independent study at Westmead IVF, higher success rates (human births) were achieved for IVF couples using MEM's lab-based prototype device, the CS10

In 2017, in preparation for developing a commercial device for use by IVF clinics, MEM built a prototype device with reusable cartridges and optimised its cartridge design and operating parameters with input from Prof. John Aitken's research team at University of Newcastle

MEM has commenced development of the clinical Felix system with Hydrix, MEM's engineering partner

Felix will have a sterile single-use cartridges with high margins, building a recurring revenue business model for MEM


**in-vitro testing of this device by ~15 leading global IVF key opinion leaders is anticipated to start in Q1 '19*



Reusable prototype cartridge test results on healthy male semen sample

For personal use only

Sample before treatment



After treatment – 6 minutes



Dead sperm

Viable sperm

Macrocephalic sperm
(large head)

- Separation of viable sperm; with no semen debris
- Intact membranes & acrosomes
- Higher average motility & morphology
- Reduced DNA damage

Key activities to clinical product launch

For personal use only

Design/build Felix 'fast prototypes'
for international KOL assessment

Conduct International KOL IVF clinics
assessment with fast prototype (15 sites)

Develop/manufacture Felix clinical system

Regulatory filings & approvals (CE, FDA)

EU/Aust
market launch
...then USA

Feb 18

4Q 19




The next application for MEM's technology: Equine Artificial Insemination ('AI')

- Memphasys and the University of Newcastle (with a National ARC Grant) are applying our sperm selection technology to equine AI
- Horses have large pregnancy failure with both natural and artificial insemination; stallions are bred for traits other than fertilising potential and sperm quality is an issue.

Semen state	Equine pregnancy rate, per cycle, with AI, (%)
Fresh	62
Chilled	45
Frozen	<30

- Lack of fertilising success leads to large economic losses for the industry and provides a commercial opportunity for MEM



NOTE: No assisted reproduction technologies, including AI, are allowed to be used with thoroughbreds for the racing industry. Despite this limitation there is a large demand for equine AI in many other breeds.

MEM's equine AI progress and strategy



- The current Felix prototype has demonstrated that it efficiently selects the most viable sperm from fresh equine semen
- MEM plans to design and build a new, purpose-built device with substantially larger cartridge volume and the high sperm yield required for equine AI.
- The equine AI industry primarily uses fresh and chilled semen; freezing is predominantly for international markets.
- MEM's technology works well with fresh semen but not so well with frozen; the freezing process not only damages the sperm but also disrupts cell surface charge.
- MEM could also process semen prior to the chilling or freezing process to ensure only the "best" quality sperm is harvested and the DNA-damaging dead cells and white blood cells are removed.

Experienced Management, Board and Partners

Management Team

Alison Coutts

Exec Chairman
*B.E (Chem), MBA,
Grad Dip Biotech*

International project management, strategy consulting, capital markets, technology commercialisation, board & senior mgt experience

Ross Harricks

Bus. Development *BE,
MBA INSEAD*

30 yrs medical device commercialisation in UK, USA and UK

Dr Jack Zhao

Senior Scientist
MD, B. Sc Biochem

Medical devices, biological research, bioprocessing

Dr Hani Nur

Senior Scientist
PhD, B.Sc (Chem)

Specialist polymer membranes development

Pablo Neyertz

CFO

Board

Alison Coutts, Chair

Andrew Goodall

Non-Exec director

International commercial property investment and management. HNW investor

John Pereira

Non-Exec director
B.Juris LLB

Funds management, banking, law, corporate advisory and capital raising for small/mid cap clients.

Technology Partners

Fertility Research

Prof John Aitken

Research Centre for Reproductive Science, Uni Newcastle

Membrane & Bio Devt

Prof Sandra Kentish

Dept of Chem and Biomolecular Eng, Melb. Uni

Design & Product Devt

Hydrix

Melbourne

Bioprocessing Strategy

Dr Tim Oldham

Tijan Ventures, Melbourne

Corporate Statistics

For personal use only

Corporate Statistics	
Shares on issue	4.45 billion
Market capitalisation	\$9.9 million @ 0.2c

Top 10 Shareholders	%
1 Andrew Goodall	29.7
2 Alison Coutts	19.9
3 Red Edge Enterprises Pty Ltd	3.9
4 Rodney Wellstead	3.9
5 J & Tw Dekker Pty Ltd	3.0
6 Nutsville Pty Ltd	2.8
7 John Aitken	2.5
8 Hawera Pty Ltd	2.2
9 Mr Adam Davey	2.0
10 Mrs Leanne Vidovich	<u>1.3</u>
	71.5

The top 20 shareholders hold 80% of the stock on issue

Investment highlights

Unique, patented sperm separation technology

- Developed with world-renowned reproduction specialist - Professor John Aitken

Felix Human IVF Application

- Proven to work; low technology risk
- Development of the next generation Felix device on track
- Need for better sperm processing for IVF
- Large, fast-growing global IVF market
- Close to having a commercial device with disposable cartridges for sale to IVF clinics globally
- Relatively small funding and time frame required

Next Application: Equine AI

- Passed proof of concept
- Substantial commercial opportunity



Thank you

Alison Coutts

Executive Chairman, *Memphasys Ltd*

30-32 Richmond Rd, Homebush NSW 2140 Australia

Phone: +612 8415 7300

Appendices

Key activities to clinical product launch

For personal use only

Cartridges & devices

- Finalise cartridge design
- Complete functional prototypes for testing
- Produce devices & cartridges for *in-vitro* trial
- Design and implement trial incl. data collection system

KOL IVF clinics recruitment & training

- Design proposed clinical programs
- Obtain MOUs for KOL clinic participation
- Recruit internal KOL support personnel
- Deliver Felix systems to KOLs & train KOLs on use

Clinical device manufacturing

- Finalise engineering development of device & cartridges
- Complete audit of potential mfrs
- Negotiate and award mfg contract
 - Manage manufacturing contract

Regulatory

- Complete reg roadmap
- Attend meetings with regulators eg FDA
- Draft technical file for reg. filings
 - Collect extra clinical data for CE, TGA, FDA
 - Set up cFDA clinical data collection in China

KOL clinical study

- Roll out study with KOL centres & collect data
- Service KOL, troubleshoot issues, collect & analyse data
 - Prepare abstracts, presentations & publications
- File CE, TGA
- File FDA

EU/Aust market launch
...then USA

Feb 18

4Q 19

Patents

	Jurisdiction	Expiry /Prov. patent application date	Held by
Cell separation	US	Oct'24	MEM
Sperm cell separation by electrophoresis*	US, Au, UK	Oct '24	Uni Newcastle
Polymeric membranes & uses thereof	US	Feb'22	MEM
Biocompatible polymeric membranes		Provisional application Apr'16	MEM
Sperm separation by electrophoresis		Provisional application Oct'16	MEM
Electrophoresis device		Provisional application Oct'16	MEM

**Uni Newcastle has granted MEM an exclusive worldwide license to apply MEM's platform separation technology to sperm separation. However, this Uni Newcastle sperm separation patent can only be used with MEM's cell separation patent and in conjunction with MEM's device for sperm separation.*

Felix development milestones achieved

2007

MEM's former lab-based machine used for successful human births in small independent *in-vivo* trial at Sydney IVF and Westmead IVF

Prof John Aitken published numerous papers in leading reproduction journals on benefits of selecting sperm based on MEM's separation method.

2008 - 2014

Development hiatus

2014

Development re-initiated under new MEM management.

Key partnerships with Minitube, Prof John Aitken (Uni Newcastle) and Prof Sandra Kentish (Uni Melb) initiated.

New research started using bovine semen.

2015 - 2016

New bio-compatible membrane & small prototype developed with improved fluid dynamics

New patenting

Successful testing and feedback on prior lab-based machine by Monash IVF Group

2017

Engineering development partner, Hydrix, engaged. New re-usable cartridge developed for optimisation studies

Successful internal and Uni Newcastle *In-vitro* optimisation studies using fresh semen

Performance specification for disposable cartridge prototype developed

\$400K NSW Medical Device Fund Grant won

2018

New Hydrix contract for developing disposable cartridges signed

Development commenced

MEM's Technology Development and Animal ART Marketing Partners

For personal use only

University of Newcastle – Prof John Aitken and his team assisting in process optimisation and testing prototype Felix cartridges, managing KOL assessment trials

Hydrix – Melbourne-based specialist medical device development partner developing the next generation Felix clinical devices

University of Melbourne Chemical and Biomolecular Engineering Department – development of a new biocompatible and readily manufactured hydrogel membrane for Felix; and ‘smart’ membranes for future commercial applications

- **Minitube GmbH** – largest global distributor of animal ART products; assisting in development of core bio-separation technology for applications with animal reproduction
- **University of NSW School of Women's & Children's Health** – will undertake further in-vitro testing and validation of Felix cartridges with types of poor male semen
- **Monash IVF Group and Westmead Fertility Centre** - small in vivo trials have demonstrated successful human births ; Felix beta test sites for clinical products

Equine AI market size statistics

For personal use only

Australia	Estimated number of registered, breeding non-thoroughbred horses in Australia	76,548
	Standard bred breeding horses*registered in Australia	22,755
	Standard bred breeding horses in Australia as % of total non-thoroughbred breeding horses registered	29.7%
	No. standard bred foals born pa in Australia (the major breed, after thoroughbreds)	6,927
	No. standard bred horses bred by AI (98.5%) in Australia	6,823
	Australia's share of equine global market	15%
Global	Estimated no. standard bred foals bred by AI	45,487
	Estimated total non-thoroughbred foals bred by AI (extra 50%)	68,231
AI costs	Approx capital cost of equipment for AI per establishment	\$4,000 - \$6000
	Approx consumables cost per AI cycle	\$300 - \$400

- Other breeds include Arabian, stock horse, quarter horse, warmblood, paint horse, appaloosa, pony
- Source: The Horse Industry, June 2001, Industry Interviews, www.horsefund.org